In a definitive M&A agreement, industrial and medical conglomerate Danaher Corp will buy diagnostics company IRIS International for $355 million.
Danaher will pay $19.50 in cash for each IRIS share, a 45.3 percent premium in this M&A deal.
Danaher said the m&a deal value comes to about $338 million, after including IRIS’ debt and net cash acquired.
The offer for all IRIS’ outstanding shares will start within the next 7 days, and will remain open for the minimum of 20 business days, IRIS said in a statement.
For further deal information visit Current Agreements (subscription required)
Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Diagnostics Partnering Yearbook 2013
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity